Chloroquine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Acute malaria As base: Initial: 600 mg, then 300 mg 6-8 hr later on day 1. Continue w/ 300 mg/day on days 2 and 3. Malaria prophylaxis As chloroquine base: 300 mg once weekly preferably same day each week, starting 1 week before exposure, continuing throughout only on a weekly basis and for at least 4 weeks after exposure. Discoid and SLE; Rheumatoid arthritis As base: Initial: 150 mg/day. Max: 2.5 mg/kg/day. Hepatic amoebiasis As base: W/ emetine or dehydroemetine: 600 mg/day for 2 days then 300 mg/day for 2-3 wk.
Administration
Should be taken with food.
Contraindications
Hypersensitivity, known or suspected resistant P. falciparum infection, porphyria, retinal damage, concurrent hepatotoxic drugs.
Special Precautions
Psoriasis, diseases of the haematopoietic or CNS systems, myasthenia gravis, hepatic or renal impairment, G6PD deficiency, epilepsy, childn. Pregnancy and lactation. Slow infusion is used upon IV admin to prevent cardiotoxicity.
Adverse Reactions
Retinopathy, hair loss, photosensitivity, tinnitus, myopathy (long-term therapy). Psychosis, seizures, leucopenia and rarely aplastic anaemia, hepatitis, GI upsets, dizziness, hypokalaemia, headache, pruritus, urticaria, difficulty in visual accommodation.
Potentially Fatal: Cardiac and respiratory arrest, CV collapse, convulsions, coma.
Drug Interactions
Concomitant therapy with phenylbutazone predisposes to dermatitis, antagonises effect of neostigmine and pyridostigmine, reduces bioavailability of ampicillin. Cimetidine inhibits metabolism of chloroquine raising plasma levels.
ATC Classification
P01BA01 - chloroquine ; Belongs to the class of aminoquinoline antimalarials.
Disclaimer: This information is independently developed by CIMS based on chloroquine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in